These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 37365416)

  • 1. Prognostic Impact of Tumor Markers (CEA and CA19-9) on Patients with Resectable Colorectal Liver Metastases Stratified by Tumor Number and Size: Potentially Valuable Biologic Markers for Preoperative Treatment.
    Kobayashi K; Ono Y; Kitano Y; Oba A; Sato T; Ito H; Mise Y; Shinozaki E; Inoue Y; Yamaguchi K; Saiura A; Takahashi Y
    Ann Surg Oncol; 2023 Nov; 30(12):7338-7347. PubMed ID: 37365416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal indication criteria for neoadjuvant chemotherapy in patients with resectable colorectal liver metastases.
    Ichida H; Mise Y; Ito H; Ishizawa T; Inoue Y; Takahashi Y; Shinozaki E; Yamaguchi K; Saiura A
    World J Surg Oncol; 2019 Jun; 17(1):100. PubMed ID: 31196104
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Post-chemotherapeutic CEA and CA19-9 are prognostic factors in patients with colorectal liver metastases treated with hepatic resection after oxaliplatin-based chemotherapy.
    Sakamoto Y; Miyamoto Y; Beppu T; Nitta H; Imai K; Hayashi H; Baba Y; Yoshida N; Chikamoto A; Baba H
    Anticancer Res; 2015 Apr; 35(4):2359-68. PubMed ID: 25862901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Is perioperative chemotherapy useful for solitary, metachronous, colorectal liver metastases?
    Adam R; Bhangui P; Poston G; Mirza D; Nuzzo G; Barroso E; Ijzermans J; Hubert C; Ruers T; Capussotti L; Ouellet JF; Laurent C; Cugat E; Colombo PE; Milicevic M
    Ann Surg; 2010 Nov; 252(5):774-87. PubMed ID: 21037433
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Perioperative carcinoembryonic antigen measurements to predict curability after liver resection for colorectal metastases: a prospective study.
    Oussoultzoglou E; Rosso E; Fuchshuber P; Stefanescu V; Diop B; Giraudo G; Pessaux P; Bachellier P; Jaeck D
    Arch Surg; 2008 Dec; 143(12):1150-8; discussion 1158-9. PubMed ID: 19075165
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemotherapy for borderline resectable colorectal cancer liver metastases: a single-institution retrospective study.
    Kitano Y; Ono Y; Kobayashi K; Oba A; Sato T; Ito H; Inoue Y; Shinozaki E; Yamaguchi K; Saiura A; Baba H; Takahashi Y
    HPB (Oxford); 2024 Feb; 26(2):282-290. PubMed ID: 37985325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High preoperative serum CA19-9 level is predictive of poor prognosis for patients with colorectal liver oligometastases undergoing hepatic resection.
    Lu Z; Peng J; Wang Z; Pan Z; Yuan Y; Wan D; Li B
    Med Oncol; 2016 Nov; 33(11):121. PubMed ID: 27722895
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor marker evolution: comparison with imaging for assessment of response to chemotherapy in patients with colorectal liver metastases.
    de Haas RJ; Wicherts DA; Flores E; Ducreux M; Lévi F; Paule B; Azoulay D; Castaing D; Lemoine A; Adam R
    Ann Surg Oncol; 2010 Apr; 17(4):1010-23. PubMed ID: 20052553
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Prognostic factors for long-term outcome of hepatic resection for colorectal liver metastases].
    Aldrighetti L; Castoldi R; Di Palo S; Arru M; Stella M; Orsenigo E; Gavazzi F; Ferla G; Di Carlo V; Staudacher C
    Chir Ital; 2005; 57(5):555-70. PubMed ID: 16241086
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic factors and survival after resection of colorectal liver metastasis in the era of preoperative chemotherapy: an 11-year single-centre study.
    John SK; Robinson SM; Rehman S; Harrison B; Vallance A; French JJ; Jaques BC; Charnley RM; Manas DM; White SA
    Dig Surg; 2013; 30(4-6):293-301. PubMed ID: 23969407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Postoperative CEA is a better prognostic marker than CA19-9, hCGβ or TATI after resection of colorectal liver metastases.
    Peltonen R; Österlund P; Lempinen M; Nordin A; Stenman UH; Isoniemi H
    Tumour Biol; 2018 Jan; 40(1):1010428317752944. PubMed ID: 29378497
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dynamic monitoring of serum CEA and CA19-9 predicts the prognosis of postoperative stage II colon cancer.
    Wang R; Xu B; Sun M; Pang X; Wang X; Zhu J; Lian J; Lu H
    Eur J Surg Oncol; 2023 Dec; 49(12):107138. PubMed ID: 37925830
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Combined detection of preoperative serum CEA, CA19-9 and CA242 improve prognostic prediction of surgically treated colorectal cancer patients.
    Wang J; Wang X; Yu F; Chen J; Zhao S; Zhang D; Yu Y; Liu X; Tang H; Peng Z
    Int J Clin Exp Pathol; 2015; 8(11):14853-63. PubMed ID: 26823815
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High CA19-9 level in resectable pancreatic cancer is a potential indication of neoadjuvant treatment.
    Ushida Y; Inoue Y; Ito H; Oba A; Mise Y; Ono Y; Sato T; Saiura A; Takahashi Y
    Pancreatology; 2021 Jan; 21(1):130-137. PubMed ID: 33303373
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Liver transplantation for nonresectable liver metastases from colorectal cancer.
    Hagness M; Foss A; Line PD; Scholz T; Jørgensen PF; Fosby B; Boberg KM; Mathisen O; Gladhaug IP; Egge TS; Solberg S; Hausken J; Dueland S
    Ann Surg; 2013 May; 257(5):800-6. PubMed ID: 23360920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Is carcino-embryonic antigen useful in the follow-up management of patients with colorectal liver metastases?
    Bakalakos EA; Burak WE; Young DC; Martin EW
    Am J Surg; 1999 Jan; 177(1):2-6. PubMed ID: 10037299
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preoperative serum CA19-9 should be routinely measured in the colorectal patients with preoperative normal serum CEA: a multicenter retrospective cohort study.
    Li Z; Zhu H; Pang X; Mao Y; Yi X; Li C; Lei M; Cheng X; Liang L; Wu J; Ding Y; Yang J; Sun Y; Zhang T; You D; Liu Z
    BMC Cancer; 2022 Sep; 22(1):962. PubMed ID: 36076189
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
    Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
    Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preoperative CA19-9: a competitive predictor of recurrence in patients with colorectal cancer liver metastases after hepatectomy.
    Liu JM; Wang YY; Liu W; Xu D; Wang K; Xing BC
    Int J Colorectal Dis; 2021 Apr; 36(4):767-778. PubMed ID: 33420522
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multicentre study of perioperative
    Allard MA; Nishioka Y; Beghdadi N; Imai K; Gelli M; Yamashita S; Kitano Y; Kokudo T; Yamashita YI; Sa Cunha A; Vibert E; Elias D; Cherqui D; Goere D; Adam R; Baba H; Hasegawa K
    BJS Open; 2019 Oct; 3(5):678-686. PubMed ID: 31592094
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.